Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Theravance Biopharma’s partner Viatris has received China's National Medical Products Administration (NMPA) approval for ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Antibiotic demand for pneumonia and COPD in the top 20 countries showed high global consumption. Researchers conducted a ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...

Breathing should be effortless . But for millions, conditions like asthma and COPD (Chronic Obstructive Pulmonary Disease) ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

The study followed 351 patients across four Korean hospitals who had received anti-tuberculosis treatment for more than six months. These individuals were monitored over 11 years (132 months) to ...

I was particularly excited about CBP-201 (now called “rademikibart”) for the treatment of inflammatory diseases such as asthma and COPD (chronic obstructive pulmonary disease). In my view, despite its ...

Australians living with chronic obstructive pulmonary disease (COPD) are being exposed to greater health risks as the use of a critical diagnostic ...